Table 2.
Distribution of patients in the retrospective cohort by timing of first symptomatic venous thromboembolism.
| Variables | VTE+ |
||||
|---|---|---|---|---|---|
| Total | Treatment phase |
||||
| Induction | Post-induction | ||||
| n | n | (%a) | n | (%a) | |
| All patients with VTE | 27 | 19 | (70) | 8 | (30) |
| Age | |||||
| < 10 years | 12 | 10 | (83) | 2 | (17) |
| ≥10 years | 15 | 9 | (60) | 6 | (40) |
| Sex | |||||
| Female | 12 | 8 | (67) | 4 | (33) |
| Male | 15 | 11 | (73) | 4 | (27) |
| Ethnicity | |||||
| Non-Hispanic | 7 | 6 | (86) | 1 | (14) |
| Hispanic | 20 | 13 | (65) | 7 | (35) |
| NCI/Rome risk group | |||||
| Standard risk B-ALL | 8 | 7 | (88) | 1 | (12) |
| High risk B-ALL | 17 | 10 | (59) | 7 | (41) |
| T-ALL | 2 | 2 | (100) | 0 | (0) |
| Induction type | |||||
| 3-drug, Dex | 8 | 7 | (88) | 1 | (12) |
| 4-drug, Dex | 2 | 2 | (100) | 0 | (0) |
| 4-drug, Pred | 17 | 10 | (59) | 7 | (41) |
| Weight category at diagnosisb | |||||
| Normal | 12 | 8 | (67) | 4 | (33) |
| Overweight | 3 | 2 | (67) | 1 | (33) |
| Obese | 12 | 9 | (75) | 3 | (25) |
a
Proportion of patients within each category who developed VTE.
b
According to CDC age/sex norms, body mass index percentile; normal ≤85%, overweight 85– < 95%, obese≥95%, VTE = venous thromboembolism, OR = Odds ratio, 95%CI = 95% Confidence Interval, NCI = National Cancer Institute, Dex = dexamethasone, Pred = prednisone.